Reuters·1 min read·hard
Merck drug extends survival in endometrial cancer trial, wins US priority review
✦AI Summary
Merck's experimental drug, sacituzumab tirumotecan, has shown success in extending survival for patients with endometrial cancer in a clinical trial. The FDA has granted the drug priority review status to expedite the approval process.
Why it matters
This represents a potential advancement in targeted cancer therapies for patients with limited treatment options.
The drug, sacituzumab tirumotecan, also known as sac-TMT, delivers a cancer-killing payload to cells that carry a protein called TROP2,…
Also covering this story
One other newsroom covered this event. We read that version too.
healthscience
✦
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in